Pfizer Inc. (PFE)

NYSE: PFE · Real-Time Price · USD
23.12
-0.27 (-1.15%)
At close: Jun 5, 2025, 4:00 PM
23.08
-0.04 (-0.17%)
After-hours: Jun 5, 2025, 4:52 PM EDT
-1.15%
Market Cap 131.45B
Revenue (ttm) 62.46B
Net Income (ttm) 7.88B
Shares Out 5.69B
EPS (ttm) 1.38
PE Ratio 16.71
Forward PE 8.21
Dividend $1.72 (7.44%)
Ex-Dividend Date May 9, 2025
Volume 33,119,503
Open 23.44
Previous Close 23.39
Day's Range 23.08 - 23.44
52-Week Range 20.92 - 31.54
Beta 0.49
Analysts Hold
Price Target 29.92 (+29.41%)
Earnings Date Jul 29, 2025

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]

Sector Healthcare
Founded 1849
Country United States
Stock Exchange NYSE
Ticker Symbol PFE
Full Company Profile

Financial Performance

In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for PFE stock is "Hold." The 12-month stock price forecast is $29.92, which is an increase of 29.41% from the latest price.

Price Target
$29.92
(29.41% upside)
Analyst Consensus: Hold
Stock Forecasts

News

These Stocks Are The High-Yield Dividend Investor's Best Friend

High-yield stocks are often riddled with flaws. However, there are some high-yield stocks available today that check all of my boxes. I share some of my top high-yield picks of the moment.

1 day ago - Seeking Alpha

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

Other symbols: AZNGILDAMGNBMYBNTXMRK
2 days ago - CNBC

Pfizer's R&D Optimization Delivers Great Results & Secure Dividends

PFE's meltdown has already triggered the richer forward dividend yields, made secure by the growing cash flow and the ongoing cost optimizations. The same has been observed in the FQ1'25 adj EPS outpe...

2 days ago - Seeking Alpha

Buy, Sell, Or Hold PFE Stock At $23?

Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a late-...

2 days ago - Forbes

June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035

My top 10 high-yield picks for June 2025 balance attractive dividend yields, strong financials, and competitive advantages to reduce risk and enhance returns. I use a rigorous four-step selection proc...

Other symbols: ARCCCNQCVSCVXJNJKHCOMC
3 days ago - Seeking Alpha

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Gold...

3 days ago - Business Wire

Pfizer (PFE) CEO on Braftovi Reducing Colorectal Cancer Death Risk "in Half"

Dr. Albert Bourla, CEO of Pfizer (PFE), joins Nicole Petallides on Morning Trade Live to discuss the latest results of his company's Braftovi drug trials. According to Dr. Bourla, results showed it ca...

5 days ago - Schwab Network

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca's Faslodex in patients with a specific gene mutation, according t...

Other symbols: ARVN
5 days ago - Reuters

Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting

Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.

Other symbols: AMGNGSKMRK
6 days ago - CNBC Television

Pfizer's BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafe...

6 days ago - Business Wire

Collaborations for Change: AUA and Pfizer Select Recipients for $1.5 Million Grant Program to Improve Advanced Prostate Cancer Care

BALTIMORE, May 29, 2025 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is excited to announce it has selected seven grant winners to split $1.5 million as part of a collaborative initia...

7 days ago - GlobeNewsWire

Hearing Against Pfizer Set For 30 May In Contraceptive ‘Depo-Provera' Multidistrict Litigation Overseen By Levin Papantonio

PENSACOLA, Fla.--(BUSINESS WIRE)--A Case Management Conference (CMC) in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Friday, 30 May at 9:00am CT in the United States...

8 days ago - Business Wire

Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline

Despite recent underperformance, a "Buy" rating on Pfizer is reiterated due to a strong Q1 EPS beat, driven by significant cost controls and margin improvement, signaling operational strength. Managem...

8 days ago - Seeking Alpha

Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates

Bispecific antibodies targeting PD1 and VEGF show promise in treating non-small cell lung cancer, with Summit Therapeutics' Ivonescimab outperforming Pembrolizumab in a Phase III trial. While immature...

10 days ago - Seeking Alpha

Stocks With the Highest Dividend Yields in the S&P 500

Ford Motor and Dow lead the list of stocks with the highest dividend yields in the S&P 500. Some of the other names might surprise you.

Other symbols: BENDOWVZWBA
10 days ago - Kiplinger

Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatme...

13 days ago - PRNewsWire

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Other symbols: MRKXRAY
14 days ago - Benzinga

Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' May Dividend Dogs

Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...

Other symbols: BBYBMYCAGETRFRTKIMLYB
15 days ago - Seeking Alpha

Pfizer Looks Like A Great Play At Current Valuations

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers. The company leads its peer group in EBITDA and revenue growth, ...

15 days ago - Seeking Alpha

SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 to Russia Company plans to export PCV13 vaccine components "We aim for the g...

15 days ago - PRNewsWire

Pfizer Pacing for 4th Day of Gains

Pfizer closes a deal on a new Cancer drug. The stock is pacing for 4th day of gains.

16 days ago - CNBC Television

Pfizer Thinks Bigger With 3SBio Deal

Pfizer Inc. decided to think bigger after the Summit deal in February and that it needs control of a PD-1/VEGF bispecific antibody versus participating with its ADC pipeline. The 3SBio deal allows inc...

16 days ago - Seeking Alpha

Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China

Pfizer (PFE) has announced a new agreement to develop and market a cancer drug currently being developed by Chinese drugmaker 3SBio.

16 days ago - Investopedia

Pfizer strikes deal with China's 3SBio to license cancer drug

CNBC's Angelica Peebles joins 'Squawk Box' to report on the latest news.

16 days ago - CNBC Television

Pfizer signs up to $6 billion licensing deal with China's 3SBio for cancer drug

Pfizer has signed a licensing agreement worth up to $6 billion with Chinese pharmaceutical products developer 3SBio Inc for the development, manufacturing and commercialization of a drug undergoing tr...

16 days ago - Reuters